jak1/tyk2 in 1

JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 [IC50 = 29 nM] and JAK1 (IC50 = 41 nM).

Tyk2-IN-9 (Compound 26), a selective Tyk-2 inhibitor, exhibits IC50 values of 0.076 nM for TYK2-JH2 and 1.8 nM for JAK1-JH2, respectively. This specificity makes it suitable for research into inflammatory or autoimmune diseases [1].

DualCathepsinL/JAK-IN-1 (Compound A8) serves as a dual inhibitor of Cathepsin L (CTSL) and JAK, exhibiting IC50 values of 0.68 μM for CTSL and 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for JAK1/2/3 and TYK2, respectively. This compound effectively prevents the activation of MAPK, NF-κB, and JAK/STAT signaling pathways, leading to significant anti-inflammatory therapeutic effects. DualCathepsinL/JAK-IN-1 is applicable in research on acute lung injury (ALI).

TYK2-IN-11 (Compound 5B) is a potent and selective inhibitor of Tyk-2, with IC50 values of 0.016 nM for TYK2-JH2 and 0.31 nM for JAK1-JH2. This compound shows potential for advancing research in inflammatory and autoimmune diseases [1].

JAK-IN-25 is a potent JAK inhibitor with IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3. JAK-IN-25 inhibits human whole blood IL-12 (HEB IL-12) with an IC50 of 28 nM, demonstrating its potential value in cancer research.

JAK-IN-30 (compound 31) is a water-soluble Janus kinase (JAK) inhibitor with IC50 values of 2 nM for JAK2, 15 nM for JAK1, 18 nM for JAK3, and 2 nM for TYK2, identified for its research potential in treating dry eye disease (DED) [1].

JAK kinase-IN-1 (Example 1) is a potent inhibitor targeting the JAK family, including TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32 nM, 27 nM, and 3473 nM, respectively [1].

JAK-IN-31 (Example 75), a JAK inhibitor, demonstrates IC50 values of ≤0.01 µM for JAK1, ≤0.01 µM for JAK2, 0.01-0.1 µM for JAK3, and ≤0.01 µM for Tyk2, indicating potent activity across these targets. It is utilized in cancer research [1].

JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].

JAK1-IN-12, a selective inhibitor of JAK1, exhibits an IC50 of 0.0246 μM and demonstrates IC50 values of 0.423 μM, 0.410 μM, and 1.12 μM for JAK2, JAK3, and TYK2, respectively. It promotes hair growth in mice and is applicable for researching immune and inflammatory diseases [1].